Market research
DPH.LSE Dechra Pharmaceuticals PLC
LSE GBP Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 4189
- Dividend yield
- Not available
- Beta
- 0.78
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- ISIN
- GB0009633180
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 4189
- Dividend yield
- Not available
- Beta
- 0.78
About
About Dechra Pharmaceuticals PLC
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, internal medicine, and nutrition products supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. It also provides water soluble antibiotics, vaccines, lameness, pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. In addition, the company distributes veterinary pharmaceuticals and equipment; markets pet diets; and develops, regulates, manufactures, and markets crop protection, as well as offers financial services. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom. As of January 16, 2024, Dechra Pharmaceuticals PLC was taken private.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the DPH.LSE discussion.
5 years, 5 months ago
Dechra Pharmaceuticals PLC is currently in a long term uptrend where the price is trading 23.6% above its 200 day moving average.
From a valuation standpoint, the stock is 98.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.5.
Dechra Pharmaceuticals PLC's total revenue sank by 0.0% to $124M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $7M since the same quarter in the previous year.
Finally, its free cash flow grew by 10.8% to $26M since the same quarter in the previous year.
Based on the above factors, Dechra Pharmaceuticals PLC gets an overall score of 3/5.